摘要
目的:观察布地奈德与异丙托溴铵气雾剂联合雾化吸入治疗慢性阻塞性肺疾病(COPD)急性发作期的疗效。方法:选择60例住院的COPD急性加重期患者,随机分为治疗组和对照组各30例。2组患者均采用吸氧、抗感染、化痰止咳平喘、维持水电解质平衡等综合治疗。治疗组在上述治疗的基础上加用布地奈德混悬液及异丙托溴铵气雾剂各2.0mL,bid,采用压缩雾化吸入机雾化吸入,连用1周。观察2组患者治疗前、后呼吸困难评分和肺功能的变化。结果:治疗1周后,2组患者的呼吸困难评分均较治疗前明显下降(P<0.05或P<0.01),且治疗组下降幅度较对照组更明显(P<0.05);2组患者的肺功能指标均较治疗前明显改善(P<0.05或P<0.01),且治疗组改善幅度较对照组更明显(P<0.05)。结论:布地奈德与异丙托溴铵联合雾化吸入治疗COPD急性发作期患者的疗效确切,能明显改善患者的肺功能和临床症状。
OBJECTIVE：To investigate the clinical efficacy of budesonide and ipratropium bromide combined with aerosol inhalation in the treatment of acute exacerbation of chronic obstructive pulmonary disease （COPD）.METHODS：60 inpatients with acute exacerbation of COPD were randomly divided into treatment group（n=30） and control groups（n=30）.Both groups received comprehensive treatment containing oxygen inhalation, antibiotics, facilitating expectoration, suppressing cough and relieving dyspnea, maintaining balance of water and electrolyte.Treatment group were additionally treated with budesonide suspension 2.0 mL and ipratropium bromide aerosols each 2.0 mL twice a day using compression aerosol inhalation machine for 1 week.The scores of dyspnea and lung function changes in 2 groups were observed before and after treatment.RESULTS：After 1 week, scores of dyspnea in 2 groups were significantly decreased after treatment（P0.05 or P0.01）, and the decrease of dyspnea scores in treatment group was more significant than in control group（P0.05）; lung function index of 2 groups was improved significantly after treatment （P0.05 or P0.01）, and the improvement of lung function in treatment group was more significant than in control group（P0.05）.CONCLUSION：Budesonide and ipratropium bromide combined with aerosol inhalation is effective in the treatment of acute exacerbation of COPD, and it can improve lung function and clinical symptoms significantly.
出处
《中国药房》
CAS
CSCD
北大核心
2010年第40期3804-3806,共3页
China Pharmacy
关键词
慢性阻塞性肺疾病
布地奈德
异丙托溴铵
雾化吸入
疗效
Chronic obstructive pulmonary disease
Budesonide
Ipratropium bromide
Aerosol inhalation
Clinical efficacy
